AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...
· FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider. · FluMist ...
The spray could be an alternative for people who are averse to getting injections, or otherwise find it difficult or ...
A nasal spray flu vaccine for people up to 49 will be available for home use starting in the fall of 2025 after the Food and ...
FluMist is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a ...
The U.S. Food and Drug Administration (FDA) has approved FluMist for self-administration. On Friday, the FDA announced that ...
The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...
FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...
First Influenza Vaccine That Does Not Need to be Administered by a Health Care Provider ...
The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the first “self-administered” influenza vaccine — though a delay in the change ...
AstraZeneca's FluMist influenza vaccine, which can be self-administered. Experts hope an option for at-home flu vaccination ...
The nasal spray option could encourage more people who have fears of doctors or needles to inoculate themselves against the ...